Once or of our and guidance after even since the I'm momentum the adjusted of [ph] good pleased end Thanks in is impact. a came solid quarter ranges call. again continuation earnings our had first and joining EBITDA, we've the above at the quarter high everyone. first beginning Andrew revenue, the all you, currency morning [ph] Thank to report earnings year. that the XXXX for
above for you in of guidance and the impact. midpoint when of currency range the $XX foreign of billion revenue million $XX adjust $X.XXX million the quarter Third range came midpoint guidance above our our
constant the you and Revenue a in currency company, is on growth range. already total pass-throughs growth revenue organic was basis. for X.X% X% adjust constant Actually, for acquisitions currency the when
second XX% From constant currency. segment Technology revenue Analytics Solutions a perspective, at grew
During the of quarter, was several businesses to growth therefore, anniversary M&A contribution in we had XXXX what tech marked quarters. about which acquired points the XXX it the we last half was basis of from is and
X% by TAS client accelerated The as constant currency almost the growth quarter was acceleration at of revenue the driven our timing came deployments. of well this organic real-world technology as in which deliverables engagement
R&D M&A. grew This at solutions growth an of impact currency. basis contribution XXX from rate from points X.X% constant by pass-throughs offset the revenue which included roughly was approximately
corner continues to is medical a This operations. turned and of Contract that solutions about sales it result integrate a to X% constant business commercial demonstrate with growing on the a our strategy has basis. currency our
low We year growth the single-digits. XXXX maybe we to to and expect CSMS flat the growth the sustain modest year-over-year the in projected business in deliver for
guidance adjusted million $XXX of end quarter Third towards EBITDA our range. of high the was
As are in I also we deployments these which acceleration, our deployments mentioned, upfront costs incur are our driving our margins. technology topline with but included
EBITDA adjusted So, in quite this strong. was context, the our performance in quarter
The end operational the our organic strong Adjusted by $X.XX our guidance and line $X.XX of $X.XX versus driven of guidance high and $X.XX was the above midpoint range EPS XX.X%. efficiency. the was of beat of performance grew below of
sales and alone, with wins XX clients win including the businesses a top wins CRM dominant the progress. XX deals OCE as and with color on some another pharma we have now competitions the a against in third for since two Both win Asia. In incumbent over the large new top XX quarter, you am pharma well signed have In space, these technology, in we marketing the give geographic were leading deals outright in in the quarter me XX and XX top the wins head-to-head to report Let to pharmas OCE the with pleased OCE I expansion. and XX our potential that to XX new Of of were deploy as client U.S. pharma launch. the deploy therapeutic OCE displacements. area the
single-arm about our real to using to spoken We've Turning supporting studies evidence. real-world success world. before you in
us clients increasingly in innovation Our this are to for looking space.
use has In that we are just months, projects arm an fact in the last comparator the quadrupled. number working of external on XX
recent pharma patient XX we utilized comparator to example, the was external project network Europe project. in to infrastructure, proprietary the was a of to very top comparator population. a For Critical QGS had client win conduct which find success with a a oncology difficult hematology/oncology to access a
Our on niche global to faster of and kind novel this infrastructure allows us clinical predictable deep insights to populations patient clients provide and path our enables a research. more
or team quarter, the real-world for with outcome provider pharma During a was our awarded a clinical company assessment also electronic ECOA XX platform. technology preferred top partnership the
Our interface improved collect the insights newly allows experience, reduced in and critical launched about This and understand to sponsors resulting patients. to cloud-based from technology transparency patient patients data. timelines, improve platform uses direct better a simple real-time
continued quarter team The of R&D. momentum their another strong excellent with bookings. to Moving
including and X.XX. basis our For was the excluding pass-throughs book-to-bill book-to-bill contracted X.XX and a as the on R&D quarter, was pass-throughs,
reporting many is we We bookings much timing services we've said quarter-to-quarter. of this than pass-throughs transparency. times the think estimates vary as are But as it and can for before meaningful less metric greatly
revenue to $XX.X contracted million X.XX, XX.X% over growing expenses. pass-throughs. backlog ended months quarter the our XX compared XX% For X.XX if by RMBS further from or expenses importantly, exclude of billion, And reimbursed including was of billion XXXX. the ratio backlog book-to-bill last next months you grew third the $X.X $XXX XX.X% reimbursed excluding and XX XX, year-over-year increased a to September
strong. growth XX have RMBS clients large acceleration of into continues power XXXX. important for supports continued to indicator now revenue our pharma metric differentiated Demand core solution. using our This forward We be our expectations capabilities
the pharma previously very client. and XX in new with a achievement let's we competitors, particularly was a two a displacement excited were account, call top during Further, locked to prominent our out This resulted them the preferred quarter agreement secure competitors. of provider
very The outsourcing R&D for and healthy. remains environment
you was RMBS the look dollars, of continues pace opportunities number pipeline as us. for at record Our a strong for whether same that year be at of XXXX, RFPs and to a
high compared teens last pipeline Our year-to-date is year. growing with
often questions The a which is healthy. I EVP segment remains of very subject know
was late-stage similar expand molecules also across oncology. growing very interestingly businesses. X% in of a XX% to As funding, pipeline of blockbuster terms funding but XXXX year. year year quarter all the The continues XXXX, of since of last which again, another you strong know, to tracking was XXXX our in is end a Once year-to-date and strong
going turn now I'm Mike, And to who it will to detail. more the review in financials
